Preoperative chemotherapy of continuous infusion of 5-fluorouracil, epirubicin or pirarubicin and cyclophosphamine in operable primary breast cancer

Chinese Journal of Cancer Research

Volumn 16, Issue 3, 2004, Pages 197-202

  Li, Jin Feng ^a   Ou, Yang Tao ^a   Wang, Tian Feng ^a   Lin, Ben Yao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

5 Fu; Breast cancer; Continuous infusion fluorouracil; Neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PIRARUBICIN; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NEUTROPHILIA; ONCOGENE NEU; PREOPERATIVE TREATMENT; THROMBOSIS; TUMOR VOLUME; VOMITING;

EID: 5344225275     PISSN: 10009604     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11670-004-0026-6     Document Type: Article

References (27)

1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J]. J Clin Oncol 1997; 15:2483-93.
2. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer [J]. J Clin Oncol 1995; 13:547-52.
3. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institute Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10:47-52.
4. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomized trial: S6 [J]. Eur J Cancer 1994; 30A:645-52.
5. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer [J]. Ann Oncol 1998; 9:1179-84.
6. Fisher B, Bryant J, Wolmark N, et al. Effects of preoperative chemotherapy on the outcome of women with operable breast cancer [J]. J Clin Oncol 1998; 16:2672-85.
7. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria [J]. Invest New Drugs 1992; 10:239-53.
8. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer [J]. Br J Cancer 977; 35:292-8.
9. Clahsen PC, van de Velde CJH, Julien JP, et al. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer [J]. J Clin Oncol 1996; 14:745-53.
10. Mauriac L, Durand M, Avril A, et al. Effects on primary chemotherapy in conservative treatment of breast cancer patients with operable tumor larger than 3 cm [J]. Ann Oncol 1991; 2:347-54.
11. Scholl SM, Pierga JY, Asselain B, et al. Breast tumor response to primary chemotherapy predicts local and distant control as well as survival [J]. Eur J Cancer 1995; 31A:1969-75.
12. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902 [J]. J Clin Oncol 2001; 19:4224-37.
13. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001; 30:5-15.
14. Mamounas EP. NSABP protocol B-27: preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel [J]. Oncology 1997; 6:37-40.
15. Dhingra K, Frye D, Newman RA, et al. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer [J]. Clin Cancer Res 1995; 1:691-7.
16. Spielamn M, Kerbrat P, Delozier T, et al. Pirarubicin in advanced breast cancer: a French cooperative phase II study [J]. Eur J Cancer 1990; 26:821-3.
17. Ansfield FJ, Ramirez G, Mackman S, et al. A 10-year study of 5-fluorouracil in disseminated breast cancer with clinical results and survival times [J]. Cancer Res 1969; 29:1062-6.
18. Carter SK. Integration of chemotherapy into combined modality treatment of solid tumors [J]. Cancer Treat Rev 1976; 3:141-74.
19. Jones RB, Shpall EJ, Shogan J, et al. The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer [J]. Cancer 1990; 66:431-6.
20. Lemon HM. Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5% dextrose [J]. Cancer Chemther Rep 1960; 8:97-101.
21. Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally by rapid intravenous and by slow infusion [J]. Cancer Res 1980; 40: 2223-8.
22. Regazzoni S, Pesce G, Marini G, et al. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer [J]. Ann Oncol 1996; 7: 807-13.
23. Cameron DA, Gabra H, Leonard NC. Continuous 5-fluorouracil in the treatment of breast cancer [J]. Br J Cancer 1994; 70:120-4.
24. Hansen R, Quebbeman E, Beatty P, et al. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast [J]. Breast Cancer Res Treat 1987; 10:145-9.
25. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study [J]. J Clin Oncol 1989; 7:425-32.
26. Collichio FA, Amamoo MA, Fogleman J, et al. Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer [J]. Am J Clin Oncol 2002; 25:194-7.
27. Nole F, Munzone E, Mandala M, et al. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study [J]. Ann Oncol 2001; 12:95-100.